Forte Biosciences (FBRX) Competitors $11.36 -0.40 (-3.40%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBRX vs. DSGN, RNAC, DRUG, NGNE, HUMA, PBYI, ACB, GLUE, FHTX, and AVIRShould you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Design Therapeutics (DSGN), Cartesian Therapeutics (RNAC), Bright Minds Biosciences (DRUG), Neurogene (NGNE), Humacyte (HUMA), Puma Biotechnology (PBYI), Aurora Cannabis (ACB), Monte Rosa Therapeutics (GLUE), Foghorn Therapeutics (FHTX), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Forte Biosciences vs. Its Competitors Design Therapeutics Cartesian Therapeutics Bright Minds Biosciences Neurogene Humacyte Puma Biotechnology Aurora Cannabis Monte Rosa Therapeutics Foghorn Therapeutics Atea Pharmaceuticals Forte Biosciences (NASDAQ:FBRX) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk. Which has more volatility & risk, FBRX or DSGN? Forte Biosciences has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Does the media prefer FBRX or DSGN? In the previous week, Forte Biosciences had 10 more articles in the media than Design Therapeutics. MarketBeat recorded 16 mentions for Forte Biosciences and 6 mentions for Design Therapeutics. Forte Biosciences' average media sentiment score of 0.42 beat Design Therapeutics' score of -0.43 indicating that Forte Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 1 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Design Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in FBRX or DSGN? 77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by insiders. Comparatively, 23.5% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend FBRX or DSGN? Forte Biosciences presently has a consensus price target of $68.00, suggesting a potential upside of 498.59%. Given Forte Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Forte Biosciences is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, FBRX or DSGN? Design Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$35.48M-$16.29-0.70Design TherapeuticsN/AN/A-$49.59M-$1.12-4.38 Is FBRX or DSGN more profitable? Design Therapeutics' return on equity of -27.15% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -85.38% -72.34% Design Therapeutics N/A -27.15%-26.07% SummaryForte Biosciences beats Design Therapeutics on 9 of the 13 factors compared between the two stocks. Get Forte Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBRX vs. The Competition Export to ExcelMetricForte BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.75M$3.12B$5.76B$9.55BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-0.7020.4630.4325.11Price / SalesN/A237.31392.2187.48Price / CashN/A42.3737.0358.50Price / Book0.767.959.016.20Net Income-$35.48M-$54.72M$3.26B$265.38M7 Day Performance4.99%1.56%1.00%-1.25%1 Month Performance12.36%5.71%4.19%-0.81%1 Year PerformanceN/A9.01%28.39%18.83% Forte Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBRXForte Biosciences2.962 of 5 stars$11.36-3.4%$68.00+498.6%+88,990.9%$74.75MN/A-0.705Earnings ReportAnalyst ForecastOptions VolumeDSGNDesign Therapeutics0.1628 of 5 stars$5.40+1.3%N/A-4.4%$303.53MN/A-4.8240News CoverageGap DownRNACCartesian Therapeutics2.3471 of 5 stars$11.28-0.4%$40.00+254.6%-23.1%$294.60M$38.91M-0.2164DRUGBright Minds Biosciences2.7047 of 5 stars$45.55+8.9%$83.25+82.8%+4,159.4%$294.58MN/A-48.98N/ANews CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionNGNENeurogene1.6863 of 5 stars$20.45-0.3%$46.17+125.8%-45.1%$292.72M$930K-4.7490HUMAHumacyte2.4068 of 5 stars$1.80-4.3%$10.64+491.3%-73.9%$291.62M$1.57M-4.00150Insider TradePBYIPuma Biotechnology4.154 of 5 stars$5.01-12.6%$7.00+39.7%+87.2%$288.63M$238.06M5.11200High Trading VolumeACBAurora Cannabis0.6059 of 5 stars$5.12+0.8%N/A-25.6%$286.79M$246.72M-26.951,130GLUEMonte Rosa Therapeutics2.0638 of 5 stars$4.56-0.4%$15.33+236.3%-24.1%$282.86M$75.62M12.6790FHTXFoghorn Therapeutics2.3102 of 5 stars$5.10+2.4%$12.00+135.3%-30.4%$281.52M$22.60M-4.29120AVIRAtea Pharmaceuticals1.7722 of 5 stars$3.53+0.9%$6.00+70.0%-7.9%$277.75MN/A-2.1970 Related Companies and Tools Related Companies DSGN Competitors RNAC Competitors DRUG Competitors NGNE Competitors HUMA Competitors PBYI Competitors ACB Competitors GLUE Competitors FHTX Competitors AVIR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBRX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access